Recent news releases
-
Oct 23, 2025 Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
-
Oct 8, 2025 Apotex supports launch of home-based cancer care with $1.5M donation
-
Oct 7, 2025 Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
-
Jul 2, 2025 Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
-
May 25, 2025 Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
-
May 20, 2025 Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
-
May 13, 2025 Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
-
May 13, 2025 Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
-
May 13, 2025 Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
-
May 13, 2025 Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre